Northern Trust Corp Has $83.40 Million Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
Several other institutional investors also recently added to or reduced their stakes in the company. FinTrust Capital Advisors LLC raised its position in NeoGenomics by 27.0% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 1,270 shares of the medical research company’s stock valued at $47,000 after buying an additional 270 shares during the last quarter. KBC Group NV bought a new stake in shares of NeoGenomics in the fourth quarter worth $56,000. RWM Asset Management LLC bought a new stake in shares of NeoGenomics in the fourth quarter worth $73,000. First Mercantile Trust Co. acquired a new position in NeoGenomics during the fourth quarter worth $89,000. Finally, Sowell Financial Services LLC grew its position in NeoGenomics by 48.2% in the fourth quarter. Sowell Financial Services LLC now owns 1,918 shares of the medical research company’s stock valued at $103,000 after purchasing an additional 624 shares in the last quarter. Institutional investors own 91.06% of the company’s stock.
NeoGenomics stock opened at $48.85 on Friday. The company has a quick ratio of 6.22, a current ratio of 6.54 and a debt-to-equity ratio of 0.25. The stock has a market cap of $5.71 billion, a PE ratio of -1,627.79 and a beta of 0.79. NeoGenomics, Inc. has a 12-month low of $23.03 and a 12-month high of $61.57. The business’s 50-day moving average price is $52.60 and its two-hundred day moving average price is $46.81.
NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Wednesday, February 24th. The medical research company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.08. The company had revenue of $126.00 million for the quarter, compared to the consensus estimate of $123.45 million. NeoGenomics had a negative net margin of 1.16% and a positive return on equity of 0.71%. The firm’s quarterly revenue was up 17.8% compared to the same quarter last year. During the same period last year, the company posted $0.06 EPS. As a group, analysts expect that NeoGenomics, Inc. will post -0.01 earnings per share for the current year.
NEO has been the subject of a number of recent analyst reports. Craig Hallum increased their price target on shares of NeoGenomics from $50.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, February 25th. Truist initiated coverage on NeoGenomics in a research report on Wednesday, January 27th. They issued a “buy” rating and a $65.00 price objective for the company. Morgan Stanley increased their price objective on shares of NeoGenomics from $46.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, March 3rd. Needham & Company LLC reiterated a “buy” rating and set a $65.00 target price on shares of NeoGenomics in a research note on Wednesday, March 3rd. Finally, BTIG Research began coverage on NeoGenomics in a report on Friday, December 11th. They set a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company. NeoGenomics presently has an average rating of “Buy” and an average price target of $48.63.
About NeoGenomics
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Featured Story: What causes a yield curve to invert?
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source